Revance Therapeutic (RVNC) DAXXIFY Approval Marks 'Transformational Shift' for Potential 'Blockbuster' Drug - William Blair
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on Revance Therapeutic (NASDAQ: RVNC) announced the FDA had granted approval ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
